Breaking News

Ablaze Pharmaceuticals and CDMO Yonghe Pharma Form Partnership

Initiate development and manufacturing services agreement for targeted radiopharmaceutical therapies.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ablaze Pharmaceuticals has initiated a development and manufacturing services agreement with Yonghe Pharmaceutical Technology to develop a series of targeted radiopharmaceutical therapy (TRT) products. Yonghe, as the CDMO partner, will provide production process development and cGMP manufacturing services for Ablaze from pharmaceutical research and preclinical activities to clinical studies. “This agreement with Yonghe represents a significant step for Ablaze in our efforts to optimize ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters